DCT

1:24-cv-00316

Pfizer Inc v. Zydus Lifesciences Ltd

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:24-cv-00316, D. Del., 07/12/2024
  • Venue Allegations: Venue is alleged to be proper for Zydus Pharmaceuticals (USA) Inc. as it has not contested venue in the district in prior litigation. Venue for Zydus Lifesciences Ltd. and Zydus Worldwide DMCC is based on their status as non-U.S. residents, allowing them to be sued in any judicial district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of Abbreviated New Drug Applications (ANDAs) to market generic versions of the sickle cell disease drug OXBRYTA® constitutes an act of patent infringement.
  • Technical Context: The lawsuit concerns patents covering crystalline forms and therapeutic dosing regimens for voxelotor, a compound that treats sickle cell disease by increasing hemoglobin's affinity for oxygen.
  • Key Procedural History: The action was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of two sets of Paragraph IV Notice Letters from Zydus. The first, dated January 23, 2024, challenged the '071 and '382 patents. The second, dated June 3, 2024, challenged the more recently issued '612 patent.

Case Timeline

Date Event
2014-02-07 Priority Date for '071 Patent
2015-12-04 Priority Date for '382 Patent and '612 Patent
2016-09-20 '071 Patent Issued
2021-06-01 '382 Patent Issued
2023-04-08 Zydus Lifesciences submits Drug Master File for voxelotor
2024-01-23 Zydus sends First Paragraph IV Notice Letters ('071 and '382 Patents)
2024-04-02 '612 Patent Issued
2024-06-03 Zydus sends Second Paragraph IV Notice Letters ('612 Patent)
2024-07-12 Second Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,447,071

  • Patent Identification: U.S. Patent No. 9,447,071, titled "Crystalline Polymorphs of the Free Base of 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde," issued September 20, 2016 (Compl. ¶11).

The Invention Explained

  • Problem Addressed: The development of a therapeutic agent requires a stable and reproducible physical form. The physicochemical properties of a compound, such as its stability and solubility, can vary between different physical forms (e.g., polymorphs), which presents a challenge for consistent manufacturing and therapeutic efficacy ('502 Patent, col. 2:5-12).
  • The Patented Solution: The patent identifies and claims a specific crystalline form of the active compound voxelotor (referred to as Compound 1), termed a "crystalline ansolvate" ('071 Patent, claim 1). This specific form, characterized by distinct X-ray powder diffraction (XRPD) data, provides the necessary stability and consistency for use in a pharmaceutical product ('502 Patent, abstract; '502 Patent, col. 4:1-12).
  • Technical Importance: Isolating and patenting a specific, stable polymorph of a drug is a critical step in pharmaceutical development, as it ensures product consistency, bioavailability, and forms a basis for regulatory approval ('502 Patent, col. 2:1-12).

Key Claims at a Glance

  • The complaint asserts at least claim 1 of the patent (Compl. ¶42).
  • Independent claim 1 requires:
    • A crystalline ansolvate of Compound 1.
    • Wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95°, and 23.92° 2θ (each ±0.2° 2θ) ('071 Patent, claim 1).

U.S. Patent No. 11,020,382

  • Patent Identification: U.S. Patent No. 11,020,382, titled "Dosing Regimens for 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde," issued June 1, 2021 (Compl. ¶12).

The Invention Explained

  • Problem Addressed: For high-dose drugs like voxelotor, complex dosing regimens can lead to poor patient adherence. There is a need to develop simple, effective dosing regimens that minimize the "pill burden" on patients to help maximize adherence and clinical outcomes ('035 Patent, col. 1:30-44).
  • The Patented Solution: The invention claims a specific method for treating sickle cell disease: administering the specific crystalline ansolvate form of Compound 1 (as claimed in the '071 patent) in an oral dose of "about 1500 mg once daily" ('382 Patent, claim 1). This establishes a specific therapeutic method combining the compound's form, dose, and frequency.
  • Technical Importance: Defining an effective once-daily dosing regimen for a chronic condition like sickle cell disease simplifies treatment for patients, which may improve adherence and therapeutic outcomes ('035 Patent, col. 1:37-44).

Key Claims at a Glance

  • The complaint asserts at least claim 1 of the patent (Compl. ¶67).
  • Independent claim 1 requires:
    • A method for treating sickle cell disease in a human patient.
    • Comprising administering Compound 1 orally in a dose of about 1500 mg once daily.
    • Wherein Compound 1 is in a specific crystalline ansolvate form characterized by particular X-ray powder diffraction peaks ('382 Patent, claim 1).

U.S. Patent No. 11,944,612

  • Patent Identification: U.S. Patent No. 11,944,612, titled "Dosing Regimens for 2-Hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde," issued April 2, 2024 (Compl. ¶13).

Multi-Patent Capsule

  • Technology Synopsis: The '612 patent also claims a method of treating sickle cell disease with the same crystalline ansolvate form of Compound 1. However, it claims a broader dosage range of "about 500 mg/day to about 1500 mg/day," providing wider protection for various potential therapeutic doses ('612 Patent, claim 10).
  • Asserted Claims: The complaint asserts at least claim 10 (Compl. ¶92).
  • Accused Features: The complaint alleges that Defendants' generic products will be administered in a dose falling within the 500 mg/day to 1500 mg/day range and will contain the claimed crystalline form of Compound 1 (Compl. ¶93).

III. The Accused Instrumentality

  • Product Identification: The accused instrumentalities are Defendants' generic voxelotor tablets and voxelotor tablets for oral suspension, for which Defendants submitted ANDA Nos. 219190 and 219192 to the FDA seeking marketing approval (Compl. ¶1; Compl. ¶17).
  • Functionality and Market Context: The accused "ANDA Products" are alleged to be generic copies of Plaintiffs' OXBRYTA® drug products, which are approved for the treatment of sickle cell disease in adults and pediatric patients (Compl. ¶¶14-15; Compl. ¶19). The ANDAs seek approval to market these generic versions before the expiration of the patents-in-suit (Compl. ¶17). The complaint alleges that Zydus's ANDA Products will contain the specific crystalline form of voxelotor (Compound 1) claimed in the patents and will be administered according to the claimed dosing regimens (Compl. ¶43; Compl. ¶68; Compl. ¶93).

IV. Analysis of Infringement Allegations

The complaint alleges that the submission of the ANDAs is an act of infringement under 35 U.S.C. § 271(e)(2)(A), and that the future commercial manufacture, use, or sale of the ANDA Products would constitute direct, induced, and contributory infringement (Compl. ¶¶39-41; Compl. ¶¶64-66; Compl. ¶¶89-91). The complaint provides the chemical structure of Compound 1 as a visual reference for the active ingredient. The image provided in the complaint shows the molecular structure of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, which is Compound 1 (Compl. p. 10).

'071 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A crystalline ansolvate of Compound 1: [structure depicted] Zydus's ANDA Products will contain a crystalline ansolvate of Compound 1. ¶43 col. 1:45-58
wherein the crystalline ansolvate is characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 13.37°, 14.37°, 19.95°, and 23.92° 2θ (each ±0.2° 2θ). The crystalline ansolvate in Zydus's ANDA Products is alleged to be characterized by at least one of these specific X-ray powder diffraction peaks. ¶43 col. 4:1-12

'382 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating sickle cell disease in a human patient in need thereof comprising administering to the patient Compound 1: [structure depicted] Zydus's ANDA Products will be used in a method for treating sickle cell disease in a human patient. ¶68 col. 27:35-50
wherein Compound 1 is administered orally in a dose of about 1500 mg once daily; Compound 1 of Zydus's ANDA Products will be administered orally in a dose of about 1500 mg once daily. ¶68 col. 27:60-61
and Compound 1 is in a crystalline ansolvate form characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37°, 14.37°, 19.95°, and 23.92° 2θ, each peak is ± 0.2° 2θ. Compound 1 in Zydus's ANDA Products is alleged to be in this specific crystalline ansolvate form. ¶68 col. 27:62-65
  • Identified Points of Contention:
    • Factual Question (Polymorph Identity): The central factual dispute will be whether the voxelotor active ingredient in Zydus's ANDA Products is, in fact, the specific crystalline ansolvate form (Form II) claimed across all three patents-in-suit. The complaint's allegations are made "upon information and belief," indicating this will be a primary focus of discovery and expert evidence (Compl. ¶43; Compl. ¶68; Compl. ¶93).
    • Legal Question (Inducement): For the method claims of the '382 and '612 patents, a key legal question will be whether the proposed product labeling for Zydus's generic products instructs, encourages, or promotes administration in a manner that falls within the claimed dosage regimens, thereby constituting inducement of infringement.

V. Key Claim Terms for Construction

  • The Term: "crystalline ansolvate"

  • Context and Importance: This term is foundational to all asserted patents, as it defines the specific physical form of the drug substance. The dispute may turn on whether Zydus's product contains this exact polymorph. Practitioners may focus on this term because any ambiguity could open the door for Zydus to argue its product uses a different, non-infringing form (e.g., a different polymorph, a solvate, or an amorphous form).

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: A party might argue that "ansolvate" should be given its plain and ordinary meaning of a crystalline solid that does not contain solvent molecules as part of its crystal lattice, without being strictly limited to the exemplified Form II.
    • Evidence for a Narrower Interpretation: The patents consistently define the claimed "crystalline ansolvate" by referencing a specific set of characteristic XRPD peaks corresponding to Form II ('071 Patent, claim 1; '382 Patent, claim 1; '612 Patent, claim 10). The related '502 patent explicitly distinguishes between multiple forms (Form I, Form II, and Material N), suggesting the patentee intended to claim a very specific polymorph, not just any non-solvated form ('502 Patent, col. 2:40-42).

  • The Term: "about 1500 mg"

  • Context and Importance: This term from claim 1 of the '382 patent defines the specific dose for the method of treatment. Its interpretation will be critical if Zydus's product is labeled for a dose close to, but not exactly, 1500 mg. The existence of the '612 patent, which claims a broad range, puts pressure on the meaning of this more specific term.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: A party could argue that in the context of clinical practice, "about" should be read to encompass doses that are therapeutically equivalent, pointing to specification disclosures of various dose levels tested in clinical development ('035 Patent, col. 1:48-50).
    • Evidence for a Narrower Interpretation: Plaintiffs may argue that the term "about 1500 mg" in the '382 patent was a deliberate choice to capture a specific optimal dose, distinguishing it from the broader range claimed later in the '612 patent. This suggests "about" should be given a narrow range to preserve the distinction between the two patents.

VI. Other Allegations

  • Indirect Infringement: Plaintiffs allege that Defendants will induce infringement by virtue of the proposed product labeling that will accompany their ANDA Products, which will instruct medical professionals and patients to administer the drug in an infringing manner (Compl. ¶¶69-70; Compl. ¶¶94-95). Contributory infringement is alleged on the basis that the ANDA Products are especially made for use in an infringing manner and are not suitable for substantial non-infringing use (Compl. ¶46; Compl. ¶71; Compl. ¶96).
  • Willful Infringement: The complaint alleges willful infringement based on Defendants' pre-suit knowledge of the patents-in-suit. This knowledge is evidenced by the Paragraph IV Notice Letters that Zydus sent to Plaintiffs, in which Zydus certified that its products would not infringe valid and enforceable claims of the patents (Compl. ¶21; Compl. ¶22; Compl. ¶44; Compl. ¶69; Compl. ¶94).

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of polymorphic identity: Does the active pharmaceutical ingredient in Zydus's generic voxelotor products possess the specific crystalline structure, as defined by the X-ray powder diffraction peaks recited in the claims of the '071, '382, and '612 patents, or is it a different, non-infringing form?
  • A second central question will be one of induced infringement: Assuming the products contain the claimed crystalline form, will the instructions on Zydus's proposed product labels direct or encourage physicians and patients to administer the drug according to the dosage regimens claimed in the '382 and '612 patents?
  • A key claim construction question may be the definitional scope of "about": How will the court construe "about 1500 mg" in the '382 patent in light of the '612 patent's broader claim to a dosage range of "about 500 mg/day to about 1500 mg/day," and how will that construction apply to the dosage information on Zydus's proposed label?